New eye drops that eliminate the need for glasses approved in India
India’s drug regulatory agency has approved new eye drops that can help people suffering from presbyopia (sight impairment) do away with their reading glasses.
New eye drops that help remove reading glasses have been approved by India’s drug regulatory agency.
Mumbai-based Entode Pharmaceuticals has developed Presvue eye drops for the treatment of presbyopia, a condition that affects 1.09 billion to 1.80 billion people worldwide.
Presbyopia occurs naturally with aging, causing difficulty focusing on close objects. It usually begins in the mid-40s and worsens until the late 60s.
ENTOD Pharmaceuticals received the final approval from the Drugs Controller General of India (DCGI) after the product was already recommended by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
PresVu is said to be the first eye drop in India designed to reduce the need for reading glasses in people suffering from presbyopia (a common vision problem that affects people over the age of 40).
The manufacturers have applied for a patent for this unique formulation and its manufacturing process.
This proprietary formula not only eliminates the need for reading glasses, but also provides the added benefit of lubricating the eyes.
The eye drops feature an advanced dynamic buffer technology, which allows them to quickly adapt to tear pH, ensuring consistent efficacy and safety for long-term use. Considering that these drops can be used for years, this feature is especially important.
Commenting on the clinical potential of PresVu, Dr. Dhananjay Bakhale said, “The approval of PresVu is a promising development in ophthalmology. For patients with presbyopia, this eye drop provides a non-invasive option that can improve near vision without the need for reading glasses.”
This can significantly impact daily life and productivity. PressVue offers a non-invasive option for improving near vision, a common challenge for people over 40, who can experience this condition when they start holding reading material at arm’s length.
Nikhil K. Masurkar, CEO of ENTOD Pharmaceuticals, highlighted the significance of this approval: “PressVu is the result of years of dedicated research and development. PressVu is not just a product; it is a solution that stands to improve the lives of millions of people by providing them with improved visual freedom.”
Dr. Aditya Sethi said that PressVue can provide an advanced option that can improve near vision within 15 minutes.
Prescription-based eye drops will be available in pharmacies from the first week of October at a price of Rs 350.
This medicine is designed for the treatment of mild to moderate presbyopia in individuals aged 40 to 55 years.
